文献速递支持与姑息治疗

电子患者报告结局与姑息治疗整合于儿童晚期癌症:PediQUEST Response多中心随机对照试验

Integrating Electronic Patient-Reported Outcomes and Palliative Care in Pediatric Advanced Cancer: The PediQUEST Response Multisite Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2026-02-04

PediQUEST Response多中心开放标签随机对照试验纳入154例晚期癌症儿童,1:1分配至电子患者报告结局(ePRO)反馈联合专科儿科姑息治疗(SPPC)组(n=74)或常规照护组(n=80),干预16周。家长报告的儿童健康相关生活质量(HRQOL)总分平均差异为3.45分(95%CI 0.48-6.43;心理社会维度和症状评分无改善。结论提示整合ePRO反馈与SPPC可能有益,但需优化实施策略。

要点

  • 改善未超过MCID 4.5分,心理社会维度和症状评分无显著改善。
  • 依从性最高的中心所有效应均超过MCID,提示实施策略影响临床获益。

核心结论

  • 整合ePRO反馈与SPPC对儿童晚期癌症HRQOL有获益趋势,但效应未超过MCID,需优化实施策略。

研究设计与样本

  • 纳入2岁及以上晚期癌症儿童,共154例随机分配至PQ Response组(n=74)或常规照护组(n=80),干预16周。

主要发现

  • 儿童报告类似改善,但效应均未超过MCID 4.5分。
  • PedsQL心理社会维度和症状评分未见改善。
  • 敏感性分析显示躯体HRQOL和部分儿童报告症状评分超过MCID,且存在中心间变异。
  • 依从性最高的中心所有效应均超过MCID,未报告不良事件。

关键数值与推荐

  • 主要终点为16周平均与基线PedsQL-4.0总分差异(范围0-100,分数越高HRQOL越好),MCID为4.5分。

临床怎么用

  • 可考虑将ePRO反馈与SPPC整合入儿童晚期癌症照护,但需关注实施依从性以最大化临床获益。

局限性

  • 效应未超过MCID,心理社会和症状维度无改善,存在中心间变异,需优化实施策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted the PediQUEST Response to the Pediatric Oncology Symptom Experience (PQ Response) randomized controlled trial (RCT) to assess whether combining feedback from an electronic patient-reported outcome (ePRO) system with specialized pediatric palliative care (SPPC) consultation improved health-related quality of life (HRQOL) in children with advanced cancer. METHODS: This multicenter open-label RCT enrolled children 2 years and older with advanced cancer. The study was conducted between April 2018 and December 2021 at five US tertiary-level pediatric cancer centers. All parents and children 5 years and older answered weekly child HRQOL and symptom surveys over 18 weeks (2-week run-in). Child-parent dyads were assigned (1:1) to PQ Response (n = 74) or usual care (n = 80) for 16 weeks. Primary outcomes were the difference between average 16-week and baseline Pediatric Quality of Life Inventory (PedsQL-4.0) total scores reported by parents and children (range, 0-100; higher = better HRQOL; minimal clinically important difference [MCID], 4.5). Secondary outcomes were PedsQL subscales and symptom scores. Analyses followed an intention-to-treat approach. RESULTS: Of 154 participants randomly assigned, 50% were girls, 78% were White, 17% were Hispanic, and 45% had brain tumors. The mean age was 11 years (standard deviation, 6.1). Parents assigned to PQ Response reported greater improvements in child HRQOL (PedsQL total mean difference 3.45 points [{95% CI, 0.48 to 6.43}; P = .023]; PedsQL physical 4.61 [{95% CI, 0.40 to 8.82}; P = .032]). Children reported similar improvements. Effects did not exceed MCIDs. No improvements were observed in PedsQL-psychosocial or symptom scores. Sensitivity analyses showed consistent effects, with most physical HRQOL scores and several child-reported symptom scores exceeding MCIDs. We observed site-specific variability. At the site with the largest adherence, all effects exceeded MCIDs. No adverse events reported. CONCLUSION: Findings suggest benefits of integrating electronic patient-reported outcome feedback and SPPC into pediatric advanced cancer care. Enhanced implementation strategies are needed to optimize clinical impact.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dussel V, Orellana L, Requena ML, et al. Integrating Electronic Patient-Reported Outcomes and Palliative Care in Pediatric Advanced Cancer: The PediQUEST Response Multisite Randomized Controlled Trial. J Clin Oncol. 2026. PMID: 41637683. doi:10.1200/JCO-25-01036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。